Importance of synovitis in osteoarthritis: Evidence for the use of glycosaminoglycans against synovial inflammation

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 5, 2014, Pages 579-587

  Henrotin, Yves ^a   Lambert, Cécile ^a   Richette, Pascal ^b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chondroitin sulfate; Glucosamine; Glycosaminoglycans; Hyaluronic acid; Osteoarthritis; Synovitis

Indexed keywords

ADIPOCYTOKINE; CHONDROITIN SULFATE; COLLAGEN; GLUCOSAMINE; GLYCOSAMINOGLYCAN; HYALURONIC ACID; INTERLEUKIN 1BETA; NEUROPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CATABOLISM; CELL ACTIVATION; CELL INFILTRATION; DISEASE SEVERITY; DRUG DEGRADATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ECHOGRAPHY; HUMAN; MEDIATOR; MEDIATOR RELEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; SYSTEMATIC REVIEW; ARTICULAR CARTILAGE; COMPLICATION; DRUG EFFECTS;

CARTILAGE, ARTICULAR; GLYCOSAMINOGLYCANS; HUMANS; HYALURONIC ACID; OSTEOARTHRITIS; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 84898802412     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.10.005     Document Type: Review

References (114)

1. Loeser R.F., Goldring S.R., Scanzello C.R., Goldring M.B. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012, 64:1697-1707.
2. Samuels J., Krasnokutsky S., Abramson S.B. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008, 66:244-250. [Epub 2008/10/22].
3. Pelletier J.P., Martel-Pelletier J., Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001, 44:1237-1247. [Epub 2001/06/16].
4. Wenham C.Y., Conaghan P.G. The role of synovitis in osteoarthritis. Ther Adv Musculoskelet Dis 2010, 2:349-359. [Epub 2010/12/01].
5. Ayral X., Pickering E.H., Woodworth T.G., Mackillop N., Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis-results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005, 13:361-367. [Epub 2005/05/11].
6. Roemer F.W., Guermazi A., Felson D.T., Niu J., Nevitt M.C., Crema M.D., et al. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann Rheum Dis 2011, 70:1804-1809. [Epub 2011/07/28].
7. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155. [Epub 2003/12/03].
8. Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681. [Epub 2004/10/09].
9. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012, 64:465-474. [Epub 2012/05/09].
10. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
11. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000.
12. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
13. Hirsch G., Kitas G., Klocke R. Intra-articular corticosteroid injection in osteoarthritis of the knee and hip: factors predicting pain relief-A systematic review. Semin Arthritis Rheum 2013, 42:451-473. [Epub 2013/02/05].
14. Maricar N., Callaghan M.J., Felson D.T., O'Neill T.W. Predictors of response to intra-articular steroid injections in knee osteoarthritis-a systematic review. Rheumatology (Oxford) 2012, 52:1022-1032. [Epub 2012/12/25].
15. Scanzello C.R., Goldring S.R. The role of synovitis in osteoarthritis pathogenesis. Bone 2012, 51:249-257. [Epub 2012/03/06].
16. Roemer F.W., Kassim Javaid M., Guermazi A., Thomas M., Kiran A., Keen R., et al. Anatomical distribution of synovitis in knee osteoarthritis and its association with joint effusion assessed on non-enhanced and contrast-enhanced MRI. Osteoarthritis Cartilage 2010, 18:1269-1274. [Epub 2010/08/10].
17. Conaghan P.G., D'Agostino M.A., Le Bars M., Baron G., Schmidely N., Wakefield R., et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis 2010, 69:644-647. [Epub 2009/05/13].
18. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013, 21:16-21.
19. Sellam J., Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010, 6:625-635. [Epub 2010/10/07].
20. Roemer F.W., Felson D.T., Yang T., Niu J., Crema M.D., Englund M., et al. The association between meniscal damage of the posterior horns and localized posterior synovitis detected on T1-weighted contrast-enhanced MRI-the MOST study. Semin Arthritis Rheum 2013, 42:573-581. [Epub 2012/12/29].
21. Adamopoulos I.E., Wordsworth P.B., Edwards J.R., Ferguson D.J., Athanasou N.A. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis. Hum Pathol 2006, 37:1176-1185.
22. Ogawa K., Mawatari M., Komine M., Shigematsu M., Kitajima M., Kukita A., et al. Mature and activated osteoclasts exist in the synovium of rapidly destructive coxarthrosis. J Bone Miner Metab 2007, 25:354-360. [Epub 2007/10/31].
23. Konttinen Y.T., Sillat T., Barreto G., Ainola M., Nordstrom D.C. Osteoarthritis as an autoinflammatory disease caused by chondrocyte-mediated inflammatory responses. Arthritis Rheum 2012, 64:613-616. [Epub 2011/12/02].
24. Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011, 23(5):471-478. [Epub 2011/07/27].
25. Bondeson J., Blom A.B., Wainwright S., Hughes C., Caterson B., van den Berg W.B. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 2010, 62:647-657. [Epub 2010/02/27].
26. Benito M.J., Veale D.J., FitzGerald O., van den Berg W.B., Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005, 64:1263-1267. [Epub 2005/02/26].
27. de Lange-Brokaar B.J., Ioan-Facsinay A., van Osch G.J., Zuurmond A.M., Schoones J., Toes R.E., et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage 2012, 20:1484-1499. [Epub 2012/09/11].
28. Scharstuhl A., Vitters E.L., van der Kraan P.M., van den Berg W.B. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum 2003, 48:3442-3451. [Epub 2003/12/16].
29. Scanzello C.R., Umoh E., Pessler F., Diaz-Torne C., Miles T., Dicarlo E., et al. Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage 2009, 17:1040-1048. [Epub 2009/03/18].
30. Nair A., Kanda V., Bush-Joseph C., Verma N., Chubinskaya S., Mikecz K., et al. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to Toll-like receptor 4 and Toll-like receptor 2 ligands via soluble CD14. Arthritis Rheum 2012, 64:2268-2277. [Epub 2012/04/12].
31. Sakkas L.I., Platsoucas C.D. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum 2007, 56:409-424. [Epub 2007/02/01].
32. Alsalameh S., Mollenhauer J., Hain N., Stock K.P., Kalden J.R., Burmester G.R. Cellular immune response toward human articular chondrocytes. T cell reactivities against chondrocyte and fibroblast membranes in destructive joint diseases. Arthritis Rheum 1990, 33:1477-1486. [Epub 1990/10/01].
33. Kotzin B.L., Falta M.T., Crawford F., Rosloniec E.F., Bill J., Marrack P., et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000, 97:291-296. [Epub 2000/01/05].
34. Kim H.Y., Kim W.U., Cho M.L., Lee S.K., Youn J., Kim S.I., et al. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255-274) in patients with rheumatoid arthritis. Arthritis Rheum 1999, 42:2085-2093. [Epub 1999/10/19].
35. Da R.R., Qin Y., Baeten D., Zhang Y. B cell clonal expansion and somatic hypermutation of Ig variable heavy chain genes in the synovial membrane of patients with osteoarthritis. J Immunol 2007, 178:557-565. [Epub 2006/12/22].
36. Shi K., Hayashida K., Kaneko M., Hashimoto J., Tomita T., Lipsky P.E., et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001, 166:650-655. [Epub 2000/12/21].
37. Smith M.D., Triantafillou S., Parker A., Youssef P.P., Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997, 24:365-371. [Epub 1997/02/01].
38. Bonnet C.S., Walsh D.A. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 2005, 44:7-16. [Epub 2004/08/05].
39. Shibakawa A., Aoki H., Masuko-Hongo K., Kato T., Tanaka M., Nishioka K., et al. Presence of pannus-like tissue on osteoarthritic cartilage and its histological character. Osteoarthritis Cartilage 2003, 11:133-140. [Epub 2003/01/30].
40. Furuzawa-Carballeda J., Macip-Rodriguez P.M., Cabral A.R. Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response. Clin Exp Rheumatol 2008, 26:554-560. [Epub 2008/09/19].
41. Sutton S., Clutterbuck A., Harris P., Gent T., Freeman S., Foster N., et al. The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J 2009, 179:10-24.
42. Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier J.P., Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011, 7:33-42. [Epub 2010/12/02].
43. Roman-Blas J.A., Jimenez S.A. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2006, 14:839-848. [Epub 2006/05/30].
44. Amos N., Lauder S., Evans A., Feldmann M., Bondeson J. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology (Oxford) 2006, 45:1201-1209. [Epub 2006/03/31].
45. Martel-Pelletier J., Alaaeddine N., Pelletier J.P. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999, 4:D694-D703. [Epub 1999/10/20].
46. Kim H.A., Cho M.L., Choi H.Y., Yoon C.S., Jhun J.Y., Oh H.J., et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006, 54:2152-2163. [Epub 2006/06/28].
47. Scanzello C.R., Plaas A., Crow M.K. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. Curr Opin Rheumatol 2008, 20:565-572. [Epub 2008/08/14].
48. Garcia-Arnandis I., Guillen M.I., Gomar F., Pelletier J.P., Martel-Pelletier J., Alcaraz M.J. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes. Arthritis Res Ther 2010, 12:R165. [Epub 2010/08/31].
49. Sakkas L.I., Scanzello C., Johanson N., Burkholder J., Mitra A., Salgame P., et al. T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis. Clin Diagn Lab Immunol 1998, 5:430-437. [Epub 1998/07/17].
50. Sakkas L.I., Johanson N.A., Scanzello C.R., Platsoucas C.D. Interleukin-12 is expressed by infiltrating macrophages and synovial lining cells in rheumatoid arthritis and osteoarthritis. Cell Immunol 1998, 188:105-110. [Epub 1998/10/03].
51. Wang Q., Rozelle A.L., Lepus C.M., Scanzello C.R., Song J.J., Larsen D.M., et al. Identification of a central role for complement in osteoarthritis. Nat Med 2011, 17:1674-1679. [Epub 2011/11/08].
52. 2! See what HIF can do!. Ann Rheum Dis 2005, 64:971-980. [Epub 2005/04/01].
53. del Rey M.J., Izquierdo E., Caja S., Usategui A., Santiago B., Galindo M., et al. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice. Arthritis Rheum 2009, 60:2926-2934. [Epub 2009/10/01].
54. Westra J., Brouwer E., Bos R., Posthumus M.D., Doornbos-van der Meer B., Kallenberg C.G., et al. Regulation of cytokine-induced HIF-1alpha expression in rheumatoid synovial fibroblasts. Ann N Y Acad Sci 2007, 1108:340-348. [Epub 2007/09/26].
55. Giatromanolaki A., Sivridis E., Maltezos E., Athanassou N., Papazoglou D., Gatter K.C., et al. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003, 5:R193-R201. [Epub 2003/06/26].
56. Yuan G.H., Tanaka M., Masuko-Hongo K., Shibakawa A., Kato T., Nishioka K., et al. Characterization of cells from pannus-like tissue over articular cartilage of advanced osteoarthritis. Osteoarthritis Cartilage 2004, 12:38-45. [Epub 2003/12/31].
57. Pozgan U., Caglic D., Rozman B., Nagase H., Turk V., Turk B. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem 2010, 391:571-579. [Epub 2010/02/26].
58. Henrotin Y., Kurz B., Aigner T. Oxygen and reactive oxygen species in cartilage degradation: friends or foes?. Osteoarthritis Cartilage 2005, 13:643-654. [Epub 2005/06/07].
59. Henrotin Y.E., Bruckner P., Pujol J.P. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003, 11:747-755. [Epub 2003/09/18].
60. Licastro F., Candore G., Lio D., Porcellini E., Colonna-Romano G., Franceschi C., et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005, 2:8. [Epub 2005/05/21].
61. Niissalo S., Hukkanen M., Imai S., Tornwall J., Konttinen Y.T. Neuropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci 2002, 966:384-399. [Epub 2002/07/13].
62. Meini S., Maggi C.A. Knee osteoarthritis: a role for bradykinin?. Inflamm Res 2008, 57:351-361. [Epub 2008/09/13].
63. Lotz M., Carson D.A., Vaughan J.H. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987, 235:893-895. [Epub 1987/02/20].
64. Mousa S.A., Straub R.H., Schafer M., Beta-endorphin Stein C. Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis 2007, 66:871-879. [Epub 2007/02/28].
65. Seidel M.F., Herguijuela M., Forkert R., Otten U. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010, 40:109-126. [Epub 2009/06/02].
66. Pottie P., Presle N., Terlain B., Netter P., Mainard D., Berenbaum F. Obesity and osteoarthritis: more complex than predicted!. Ann Rheum Dis 2006, 65:1403-1405. [Epub 2006/10/14].
67. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R.E., Gay S., et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007, 56:2829-2839. [Epub 2007/09/01].
68. Presle N., Pottie P., Dumond H., Guillaume C., Lapicque F., Pallu S., et al. Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 2006, 14:690-695. [Epub 2006/03/11].
69. Mapp P.I., Avery P.S., McWilliams D.F., Bowyer J., Day C., Moores S., et al. Angiogenesis in two animal models of osteoarthritis. Osteoarthritis Cartilage 2008, 16:61-69. [Epub 2007/07/31].
70. Mapp P.I., Walsh D.A. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol 2012, 8:390-398. [Epub 2012/05/30].
71. Haywood L., McWilliams D.F., Pearson C.I., Gill S.E., Ganesan A., Wilson D., et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003, 48:2173-2177. [Epub 2003/08/09].
72. Walsh D.A., Bonnet C.S., Turner E.L., Wilson D., Situ M., McWilliams D.F. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage 2007, 15:743-751. [Epub 2007/03/23].
73. Walsh D.A. Pathophysiological mechanisms of angiogenesis. Adv Clin Chem 2007, 44:187-221. [Epub 2007/08/09].
74. Walsh D.A. Angiogenesis in osteoarthritis and spondylosis: successful repair with undesirable outcomes. Curr Opin Rheumatol 2004, 16:609-615. [Epub 2004/08/18].
75. Koch A.E., Burrows J.C., Haines G.K., Carlos T.M., Harlan J.M., Leibovich S.J. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 1991, 64:313-320. [Epub 1991/03/01].
76. Walsh D.A., Wade M., Mapp P.I., Blake D.R. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol 1998, 152:691-702. [Epub 1998/03/21].
77. Henrotin Y., Mathy M., Sanchez C., Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis 2010, 2:335-348. [Epub 2010/12/01].
78. Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology 2011, 19:299-306. [Epub 2011/11/02].
79. Omata T., Itokazu Y., Inoue N., Segawa Y. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung 2000, 50:148-153. [Epub 2000/03/17].
80. Campo G.M., Avenoso A., Campo S., Ferlazzo A.M., Altavilla D., Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 2003, 5:R122-R131. [Epub 2003/05/02].
81. Cho S.Y., Sim J.S., Jeong C.S., Chang S.Y., Choi D.W., Toida T., et al. Effects of low molecular weight chondroitin sulfate on type II collagen-induced arthritis in DBA/1J mice. Biol Pharm Bull 2004, 27:47-51. [Epub 2004/01/08].
82. Chou M.M., Vergnolle N., McDougall J.J., Wallace J.L., Marty S., Teskey V., et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) 2005, 230:255-262. [Epub 2005/03/29].
83. Bauerova K., Ponist S., Kuncirova V., Mihalova D., Paulovicova E., Volpi N. Chondroitin sulfate effect on induced arthritis in rats. Osteoarthritis Cartilage 2011, 19:1373-1379.
84. Campo G.M., Avenoso A., Campo S., D'Ascola A., Ferlazzo A.M., Calatroni A. Reduction of DNA fragmentation and hydroxyl radical production by hyaluronic acid and chondroitin-4-sulphate in iron plus ascorbate-induced oxidative stress in fibroblast cultures. Free Radic Res 2004, 38:601-611. [Epub 2004/09/07].
85. Jin M., Iwamoto T., Yamada K., Satsu H., Totsuka M., Shimizu M. Effects of chondroitin sulfate and its oligosaccharides on Toll-like receptor-mediated IL-6 secretion by macrophage-like J774.1 cells. Biosci Biotechnol Biochem 2011, 75:1283-1289.
86. David-Raoudi M., Deschrevel B., Leclercq S., Galera P., Boumediene K., Pujol J.P. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: role of p38 and Akt. Arthritis Rheum 2009, 60:760-770. [Epub 2009/02/28].
87. Imada K., Oka H., Kawasaki D., Miura N., Sato T., Ito A. Anti-arthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Biol Pharm Bull 2010, 33:410-414. [Epub 2010/03/02].
88. Lambert C., Mathy-Hartert M., Dubuc J.E., Montell E., Verges J., Munaut C., et al. Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther 2012, 14:R58. [Epub 2012/03/14].
89. Henrotin Y., Mobasheri A., Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?. Arthritis Res Ther 2012, 14:201. [Epub 2012/02/02].
90. Jawed H., Anjum S., Awan S.I., Simjee S.U. Anti-arthritic effect of GN1, a novel synthetic analog of glucosamine, in the collagen-induced arthritis model in rats. Inflamm Res 2011, 60:1113-1120. [Epub 2011/08/30].
91. Ivanovska N., Dimitrova P. Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res Ther 2011, 13:R44. [Epub 2011/03/18].
92. Uitterlinden E.J., Koevoet J.L., Verkoelen C.F., Bierma-Zeinstra S.M., Jahr H., Weinans H., et al. Glucosamine increases hyaluronic acid production in human osteoarthritic synovium explants. BMC Musculoskelet Disord 2008, 9:120. [Epub 2008/09/13].
93. Igarashi M., Kaga I., Takamori Y., Sakamoto K., Miyazawa K., Nagaoka I. Effects of glucosamine derivatives and uronic acids on the production of glycosaminoglycans by human synovial cells and chondrocytes. Int J Mol Med 2011, 27:821-827. [Epub 2011/04/02].
94. Nakamura H., Shibakawa A., Tanaka M., Kato T., Nishioka K. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004, 22:293-299. [Epub 2004/05/18].
95. Kim M.M., Mendis E., Rajapakse N., Kim S.-K. Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect. Bioorg Med Chem Lett 2007, 17:1938-1942.
96. Tsai W.-Y., Wu J.-L., Liu C.-C., Cherng C.-H., Tsai R.-Y., Jean Y.-H., et al. Early intraarticular injection of hyaluronic acid attenuates osteoarthritis progression in anterior cruciate ligament-transected rats. Connect Tissue Res 2012, 54:49-54.
97. Cake M.A., Smith M.M., Young A.A., Smith S.M., Ghosh P., Read R.A. Synovial pathology in an ovine model of osteoarthritis: effect of intraarticular hyaluronan (Hyalgan). Clin Exp Rheumatol 2008, 26:561-567. [Epub 2008/09/19].
98. Smith M.M., Cake M.A., Ghosh P., Schiavinato A., Read R.A., Little C.B. Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy. Rheumatology (Oxford) 2008, 47:1172-1178. [Epub 2008/06/21].
99. Chou L.W., Wang J., Chang P.L., Hsieh Y.L. Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model. Arthritis Res Ther 2011, 13:R90. [Epub 2011/06/18].
100. Wiig M.E., Amiel D., VandeBerg J., Kitabayashi L., Harwood F.L., Arfors K.E. The early effect of high molecular weight hyaluronan (hyaluronic acid) on anterior cruciate ligament healing: an experimental study in rabbits. J Orthop Res 1990, 8:425-434. [Epub 1990/05/01].
101. Campo G.M., Avenoso A., Nastasi G., Micali A., Prestipino V., Vaccaro M., et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta 2011, 1812:1170-1181. [Epub 2011/07/05].
102. Punzi L. The complexity of the mechanisms of action of hyaluronan in joint diseases. Clin Exp Rheumatol 2001, 19:242-246. [Epub 2001/06/16].
103. Karatay S., Kiziltunc A., Yildirim K., Karanfil R.C., Senel K. Effects of different hyaluronic acid products on synovial fluid NO levels in knee osteoarthritis. Clin Rheumatol 2005, 24:497-501. [Epub 2005/05/21].
104. Karatay S., Kiziltunc A., Yildirim K., Karanfil R.C., Senel K. Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis. Ann Clin Lab Sci 2004, 34:330-335.
105. Carlos T.M., Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 1994, 84:2068-2101. [Epub 1994/10/01].
106. Wang C.T., Lin Y.T., Chiang B.L., Lin Y.H., Hou S.M. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage 2006, 14:1237-1247.
107. Pasquali Ronchetti I., Guerra D., Taparelli F., Boraldi F., Bergamini G., Mori G., et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. Rheumatology (Oxford) 2001, 40:158-169. [Epub 2001/03/21].
108. Schumacher H.R., Paul C., Hitchon C.A., El-Gabalawy H., Zonay L., Clayburne G., et al. Hyaluronate effects on synovium and synovial fluid. A prospective blinded study in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2006, 14:501-503.
109. Kataoka Y., Ariyoshi W., Okinaga T., Kaneuji T., Mitsugi S., Takahashi T., et al. Mechanisms involved in suppression of ADAMTS4 expression in synoviocytes by high molecular weight hyaluronic acid. Biochem Biophys Res Commun 2013, 432:580-585.
110. Huang T.-L., Hsu H.-C., Yang K.-C., Lin F.-H. Hyaluronan up-regulates IL-10 expression in fibroblast-like synoviocytes from patients with tibia plateau fracture. J Orthop Res 2011, 29:495-500.
111. Goldberg R.L., Toole B.P. Hyaluronate inhibition of cell proliferation. Arthritis Rheum 1987, 30:769-778.
112. Park D., Kim Y., Kim H., Kim K., Lee Y.-S., Choe J., et al. Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFβ receptor interaction via CD44-PKCδ. Mol Cells 2012, 33:563-574.
113. Campo G.M., Avenoso A., D'Ascola A., Scuruchi M., Prestipino V., Nastasi G., et al. The inhibition of hyaluronan degradation reduced pro-inflammatory cytokines in mouse synovial fibroblasts subjected to collagen-induced arthritis. J Cell Biochem 2012, 113:1852-1867. [Epub 2012/01/12].
114. Hochberg M., Chevalier X., Henrotin Y., Hunter D.J., Uebelhart D. Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence?. Curr Med Res Opin 2012, 29:259-267.